Display options
Cite
Cipollone F, Di Fabio S, Bucci M, et al. Angiotensin II Blockade and Total Cardiovascular Risk : Beyond Blood Pressure Reduction. High Blood Press Cardiovasc Prev. 2013;15(4):245-53doi: 10.2165/0151642-200815040-00004.
Cipollone, F., Di Fabio, S., Bucci, M., Cicolini, G., & Mezzetti, A. (2008). Angiotensin II Blockade and Total Cardiovascular Risk : Beyond Blood Pressure Reduction. High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, 15(4), 245-53. https://doi.org/10.2165/0151642-200815040-00004
Cipollone, Francesco, et al. "Angiotensin II Blockade and Total Cardiovascular Risk : Beyond Blood Pressure Reduction." High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension vol. 15,4 (2008): 245-53. doi: https://doi.org/10.2165/0151642-200815040-00004
Cipollone F, Di Fabio S, Bucci M, Cicolini G, Mezzetti A. Angiotensin II Blockade and Total Cardiovascular Risk : Beyond Blood Pressure Reduction. High Blood Press Cardiovasc Prev. 2008 Oct;15(4):245-53. doi: 10.2165/0151642-200815040-00004. Epub 2013 Jan 22. PMID: 23355127.
Copy Download .nbib Format: NLM
Share it on

High Blood Press Cardiovasc Prev. 2008 Oct;15(4):245-53. doi: 10.2165/0151642-200815040-00004. Epub 2013 Jan 22.

Angiotensin II Blockade and Total Cardiovascular Risk : Beyond Blood Pressure Reduction.

High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension

Francesco Cipollone, Sara Di Fabio, Marco Bucci, Giancarlo Cicolini, Andrea Mezzetti

Affiliations

  1. Italian Society for the Study of Atherosclerosis Abruzzo Section, Centro di Riferimento Regionale per l'Aterosclerosi, l'Ipertensione Arteriosa e le Dislipidemie, Policlinico Clinicizzato "Santissima Annunziata", Via Colle dell'Ara, 66013, Chieti, Italy, [email protected].

PMID: 23355127 DOI: 10.2165/0151642-200815040-00004

Abstract

Hypertension is one of the world's largest public health problems and it is both a disease and a risk factor for cardiovascular disease (CVD). The heart, the endothelium and the kidneys are the target organs of hypertension. Recently, several antihypertensive drugs have been introduced to the market; therefore, the choice is mainly determined by the patients' features. In particular, ACE inhibitors and angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs]) demonstrate a larger reduction in cardiovascular risk than other antihypertensive treatments because of the existence of blood pressure-independent effects. In fact, the angiotensin II pathway plays a major role in metabolic, haemodynamic and endothelial homeostasis. For these reasons, ACE inhibitors and ARBs have primary indications in patients with obesity, hypercholesterolaemia and diabetes mellitus because of their favourable metabolic properties. Furthermore, several large trials have demonstrated that they have favourable effects also in patients with left ventricular dysfunction or systolic heart failure, as well as other forms of heart disease. Drugs affecting the angiotensin II pathway may reduce endothelial dysfunction through several mechanisms including reduction of vascular permeability and oxidative stress. Another important effect of these drugs is neuroprotection. This is an important effect because in the near future, due to an aging population, an important goal for optimal antihypertensive treatment will be the prevention of cognitive decline. ACE inhibitors and ARBs are very important drugs in the modern management of the total cardiovascular risk in hypertensive patients.

References

  1. Curr Opin Nephrol Hypertens. 2000 Mar;9(2):133-8 - PubMed
  2. Lab Invest. 2002 Jun;82(6):747-56 - PubMed
  3. N Engl J Med. 2003 Nov 13;349(20):1893-906 - PubMed
  4. Hypertension. 2005 Feb;45(2):185-6 - PubMed
  5. Ann Intern Med. 2003 Jul 15;139(2):137-47 - PubMed
  6. J Clin Hypertens (Greenwich). 2008 Jan;10(1 Suppl 1):4-12 - PubMed
  7. Circulation. 2002 Jan 29;105(4):530-6 - PubMed
  8. Circulation. 1996 Dec 1;94(11):2756-67 - PubMed
  9. J Clin Invest. 1995 Jul;96(1):60-8 - PubMed
  10. Prog Cardiovasc Dis. 1997 Jan-Feb;39(4):325-42 - PubMed
  11. Circulation. 2004 Dec 21;110(25):3849-57 - PubMed
  12. Am J Med Sci. 2002 Jan;323(1):17-24 - PubMed
  13. Metabolism. 2006 Sep;55(9):1159-64 - PubMed
  14. Am J Hypertens. 2000 Jan;13(1 Pt 2):3S-10S - PubMed
  15. Diabetes. 2006 Dec;55(12):3550-5 - PubMed
  16. Am J Cardiovasc Drugs. 2005;5(4):245-53 - PubMed
  17. Am J Med. 2008 Aug;121(8 Suppl):S8-15 - PubMed
  18. Hypertension. 2004 Jul;44(1):12-9 - PubMed
  19. Circulation. 2003 Aug 12;108(6):684-90 - PubMed
  20. Circulation. 2005 Jun 28;111(25):3481-8 - PubMed
  21. J Am Soc Nephrol. 2004 Jun;15(6):1616-22 - PubMed
  22. J Cardiovasc Pharmacol. 2001 Apr;37 Suppl 1:S11-20 - PubMed
  23. N Engl J Med. 1987 Jun 4;316(23):1429-35 - PubMed
  24. Trends Pharmacol Sci. 2003 Sep;24(9):471-8 - PubMed
  25. J Clin Invest. 1987 Jan;79(1):1-6 - PubMed
  26. Circulation. 1997 Jan 21;95(2):473-8 - PubMed
  27. Lancet. 2003 Sep 6;362(9386):767-71 - PubMed
  28. Lancet. 2003 Sep 6;362(9386):782-8 - PubMed
  29. Adv Ther. 2007 Jan-Feb;24(1):146-53 - PubMed
  30. J Clin Pharm Ther. 2007 Jun;32(3):261-8 - PubMed
  31. Arterioscler Thromb Vasc Biol. 2000 Mar;20(3):645-51 - PubMed
  32. J Cardiometab Syndr. 2006 Winter;1(1):29-35 - PubMed
  33. Circulation. 1993 May;87(5):1475-81 - PubMed
  34. Drugs. 2004;64(22):2537-65 - PubMed
  35. Am J Med. 2008 Aug;121(8 Suppl):S16-22 - PubMed
  36. Public Health Nutr. 2007 Oct;10(10A):1151-5 - PubMed
  37. Ther Adv Cardiovasc Dis. 2007 Dec;1(2):97-106 - PubMed
  38. Vasc Health Risk Manag. 2008;4(1):89-101 - PubMed
  39. Lancet. 1987 Nov 7;2(8567):1057-8 - PubMed
  40. Circ Res. 1999 May 14;84(9):1043-9 - PubMed
  41. Circ Res. 2000 Nov 10;87(10):840-4 - PubMed
  42. Medscape J Med. 2008 Mar 26;10 Suppl:S6 - PubMed
  43. Can J Cardiol. 2004 Aug;20 Suppl B:77B-82B - PubMed
  44. Circulation. 1999 Oct 12;100(15):1646-52 - PubMed
  45. Minerva Med. 2004 Oct;95(5):395-409 - PubMed
  46. Curr Opin Nephrol Hypertens. 2006 Jul;15(4):361-5 - PubMed
  47. Ann Pharmacother. 2008 Jul;42(7):925-32 - PubMed
  48. Nephrol Dial Transplant. 2008 Oct;23(10):3174-83 - PubMed
  49. J Hypertens. 2007 May;25(5):951-8 - PubMed
  50. Hypertension. 1998 Dec;32(6):1044-8 - PubMed
  51. J Cardiovasc Nurs. 2005 Sep-Oct;20(5):354-64 - PubMed
  52. Circulation. 2006 Jul 4;114(1 Suppl):I296-301 - PubMed
  53. J Cardiovasc Risk. 2003 Apr;10(2):121-8 - PubMed
  54. Circulation. 2004 Mar 30;109(12):1536-42 - PubMed
  55. N Engl J Med. 2000 Jan 20;342(3):145-53 - PubMed
  56. J Clin Invest. 1993 Apr;91(4):1453-8 - PubMed
  57. Hypertension. 2000 Jan;35(1 Pt 2):353-9 - PubMed
  58. N Engl J Med. 2008 Apr 10;358(15):1547-59 - PubMed
  59. Presse Med. 2002 Nov 9;31(36):1714-20 - PubMed
  60. Circulation. 2000 Oct 24;102(17):2118-23 - PubMed
  61. Lancet. 2003 Sep 6;362(9386):777-81 - PubMed
  62. Am Heart J. 1991 Apr;121(4 Pt 1):1244-63 - PubMed
  63. Circulation. 1999 Aug 31;100(9):899-902 - PubMed
  64. J Nephrol. 2004 Jul-Aug;17(4):512-9 - PubMed
  65. Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4651-5 - PubMed
  66. Am J Hypertens. 2000 Jul;13(7):783-8 - PubMed
  67. Vasc Health Risk Manag. 2007;3(6):937-45 - PubMed
  68. J Hypertens Suppl. 2005 Apr;23(1):S9-17 - PubMed
  69. J Am Soc Nephrol. 2002 Sep;13(9):2213-22 - PubMed
  70. J Am Coll Cardiol. 2000 Dec;36(7):2287-95 - PubMed
  71. Diabetes Res Clin Pract. 2007 Aug;77(2):210-4 - PubMed
  72. Curr Pharm Des. 2007;13(10):1053-68 - PubMed
  73. Stroke. 2005 Jun;36(6):1218-26 - PubMed
  74. CNS Drugs. 2002;16(3):145-53 - PubMed
  75. Circulation. 2000 Oct 17;102(16):1970-6 - PubMed
  76. Coron Artery Dis. 1999 Jun;10(4):241-56 - PubMed
  77. Br J Biomed Sci. 2003;60(4):191-6 - PubMed
  78. Hypertens Res. 2007 Nov;30(11):1119-28 - PubMed

Publication Types